Exact Sciences reported strong financial and operational performance with significant revenue growth driven by Cologuard and new product launches. However, there were challenges in maintaining gross margins and completing payer contracts for Cologuard Plus.

Company Guidance

During Exact Sciences' third-quarter 2025 earnings call, the company provided updated guidance, reflecting a strong performance and increased outlook for the year. The company reported a 20% year-over-year revenue growth to $851 million, driven by the success of their Cologuard test, which contributed to a screening revenue increase of 22% to $666 million. The Precision Oncology segment also grew by 12% to $183 million. Adjusted EBITDA rose by 37% to $135 million, with margins expanding by 200 basis points to 16%. The company raised its full-year revenue guidance to between $3.22 billion and $3.235 billion and adjusted EBITDA guidance to between $470 million and $480 million. They highlighted the launch of Cancerguard, a multi-cancer early detection test, and the expansion of patient access to Cologuard Plus, which offers improved sensitivity and specificity. The call emphasized the company's strategic focus on driving commercial effectiveness, leveraging their ExactNexus platform, and building momentum across their product portfolio to achieve long-term growth and meet 2027 financial targets.

Record Revenue Growth

Exact Sciences reported a 20% year-over-year increase in total revenue, reaching $851 million, marking the highest quarterly growth rate in over two years.

Cologuard Plus Success

The launch of Cologuard Plus demonstrated 95% sensitivity and 94% specificity, with positive coverage decisions from the top 10 payers, contributing significantly to the revenue growth.

Strong Financial Performance

Adjusted EBITDA grew by 37% year-over-year to $135 million, with margins expanding by 200 basis points to 16%. Free cash flow increased by $77 million to $190 million for the quarter.

Cancerguard Launch

The company launched Cancerguard, a multi-cancer early detection test, aiming to address the low percentage of cancers found through screening.

Precision Oncology Growth

Precision Oncology revenue increased by 12% year-over-year on a core basis to $183 million, driven by Oncotype DX expansion and partner revenues.

Exact Sciences (EXAS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

EXAS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 24, 2026	2025 (Q4)	-0.03 / -	-4.67	―	―	―
Nov 03, 2025	2025 (Q3)	-0.06 / -0.10	-0.21	52.38% (+0.11)
Aug 06, 2025	2025 (Q2)	-0.13 / -0.01	-0.09	88.89% (+0.08)
May 01, 2025	2025 (Q1)	-0.36 / -0.54	-0.6	10.00% (+0.06)
Feb 19, 2025	2024 (Q4)	-0.30 / -4.67	-0.27	-1629.63% (-4.40)
Nov 05, 2024	2024 (Q3)	-0.20 / -0.21	0	―
Jul 31, 2024	2024 (Q2)	-0.34 / -0.09	-0.45	80.00% (+0.36)
May 08, 2024	2024 (Q1)	-0.48 / -0.60	-0.42	-42.86% (-0.18)
Feb 21, 2024	2023 (Q4)	-0.44 / -0.27	-0.72	62.50% (+0.45)
Nov 01, 2023	2023 (Q3)	-0.47 / 0.00	-0.84	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

EXAS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 03, 2025	$66.98	$69.59	+3.90%
Aug 06, 2025	$46.91	$43.16	-7.99%
May 01, 2025	$47.16	$51.55	+9.31%
Feb 19, 2025	$50.48	$49.51	-1.92%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Exact Sciences Corp. (EXAS) report earnings?

Exact Sciences Corp. (EXAS) is schdueled to report earning on Feb 24, 2026, After Close (Confirmed).

What is Exact Sciences Corp. (EXAS) earnings time?

Exact Sciences Corp. (EXAS) earnings time is at Feb 24, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is EXAS EPS forecast?

EXAS EPS forecast for the fiscal quarter 2025 (Q4) is -0.03.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing